Vale Pharma Ltd 31/01/2025 iXBRL

Company registration number: 06469546

Vale Pharma Ltd

Unaudited filleted financial statements

31 January 2025

Vale Pharma Ltd

Contents

Directors and other information

Accountants report

Statement of financial position

Statement of changes in equity

Notes to the financial statements

Vale Pharma Ltd

Directors and other information


	Directors	Mr M Z Karim
		Mr M B Karim


	Secretary	Mr M B Karim


	Company number	06469546


	Registered office	2 Grimscar Avenue
		Birkby
		Huddersfield
		West Yorkshire
		HD2 2TW


	Accountants	Accounts Tax Solutions Limited
		3, Grove Street
		Wilmslow
		Cheshire
		SK9 1DU

Vale Pharma Ltd

Report to the board of directors on the preparation of the

unaudited statutory financial statements of Vale Pharma Ltd

Year ended 31 January 2025

As described on the statement of financial position, the directors of the company are responsible for the preparation of the financial statements for the year ended 31 January 2025 which comprise the statement of financial position, statement of changes in equity and related notes.

You consider that the company is exempt from an audit under the Companies Act 2006. In accordance with your instructions we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to us.

Accounts Tax Solutions Limited

3, Grove Street

Wilmslow

Cheshire

SK9 1DU

11 September 2025

Vale Pharma Ltd

Statement of financial position

31 January 2025

		2025		2024
	Note	£	£	£	£

Fixed assets
Intangible assets	5	300,000		375,000
Tangible assets	6	6,044		5,509
		_______		_______
			306,044		380,509

Current assets
Stocks		54,153		52,653
Debtors	7	118,198		119,865
Cash at bank and in hand		435,538		398,002
		_______		_______
		607,889		570,520
Creditors: amounts falling due
within one year	8	( 810,090)		( 810,413)
		_______		_______
Net current liabilities			( 202,201)		( 239,893)
			_______		_______
Total assets less current liabilities			103,843		140,616

			_______		_______
Net assets			103,843		140,616
			_______		_______

Capital and reserves
Called up share capital			8		8
Profit and loss account			103,835		140,608
			_______		_______
Shareholders funds			103,843		140,616
			_______		_______

For the year ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 11 September 2025 , and are signed on behalf of the board by:

Mr M Z Karim

Director

Company registration number: 06469546

Vale Pharma Ltd

Statement of changes in equity

Year ended 31 January 2025

	Called up share capital	Profit and loss account	Total
	£	£	£


At 1 February 2023	8	163,581	163,589

Loss for the year		( 22,973)	( 22,973)
	_______	_______	_______
Total comprehensive income for the year	-	( 22,973)	( 22,973)

	_______	_______	_______
At 31 January 2024 and 1 February 2024	8	140,608	140,616

Loss for the year		( 36,773)	( 36,773)
	_______	_______	_______
Total comprehensive income for the year	-	( 36,773)	( 36,773)

	_______	_______	_______
At 31 January 2025	8	103,835	103,843
	_______	_______	_______

Vale Pharma Ltd

Notes to the financial statements

Year ended 31 January 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 2 Grimscar Avenue, Birkby, Huddersfield, West Yorkshire, HD2 2TW.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Goodwill

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:


Fittings fixtures and equipment	-	25 %	reducing balance
Motor vehicles	-	25 %	reducing balance

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 11 (2024: 9 ).

5. Intangible assets

	Goodwill	Total
	£	£
Cost
At 1 February 2024 and 31 January 2025	1,500,000	1,500,000
	_______	_______
Amortisation
At 1 February 2024	1,125,000	1,125,000
Charge for the year	75,000	75,000
	_______	_______
At 31 January 2025	1,200,000	1,200,000
	_______	_______
Carrying amount
At 31 January 2025	300,000	300,000
	_______	_______
At 31 January 2024	375,000	375,000
	_______	_______

6. Tangible assets

	Fixtures, fittings and equipment	Motor vehicles	Total
	£	£	£
Cost
At 1 February 2024	30,060	9,741	39,801
Additions	2,550	-	2,550
	_______	_______	_______
At 31 January 2025	32,610	9,741	42,351
	_______	_______	_______
Depreciation
At 1 February 2024	26,876	7,416	34,292
Charge for the year	1,434	581	2,015
	_______	_______	_______
At 31 January 2025	28,310	7,997	36,307
	_______	_______	_______
Carrying amount
At 31 January 2025	4,300	1,744	6,044
	_______	_______	_______
At 31 January 2024	3,184	2,325	5,509
	_______	_______	_______

7. Debtors

	2025	2024
	£	£
Other debtors	118,198	119,865
	_______	_______

8. Creditors: amounts falling due within one year

	2025	2024
	£	£
Bank loans and overdrafts	1	1
Trade creditors	149,846	146,676
Corporation tax	9,380	13,726
Social security and other taxes	3,143	3,143
Other creditors	647,720	646,867
	_______	_______
	810,090	810,413
	_______	_______

9. Directors advances, credits and guarantees

	During the year the directors entered into the following advances and credits with the company:

2025
		Balance brought forward	Advances /(credits) to the directors	Balance o/standing
		£	£	£
	Mr M Z Karim	( 226,774)	( 600)	( 227,374)
	Mr M B Karim	( 267,796)	( 600)	( 268,396)
		_______	_______	_______
		( 494,570)	( 1,200)	( 495,770)
		_______	_______	_______

2024
		Balance brought forward	Advances /(credits) to the directors	Balance o/standing
		£	£	£
	Mr M Z Karim	( 226,174)	( 600)	( 226,774)
	Mr M B Karim	( 267,196)	( 600)	( 267,796)
		_______	_______	_______
		( 493,370)	( 1,200)	( 494,570)
		_______	_______	_______

10. Controlling party

The ultimate controlling party of the company are its Director.